Effect of tighter glycemic control on cardiac function, exercise capacity, and muscle strength in heart failure patients with type 2 diabetes: A randomized study

BMJ Open Diabetes Research and Care

Volumn 4, Issue 1, 2016, Pages

  Nielsen, Roni ^a,b   Wiggers, Henrik ^a   Thomsen, Henrik Holm ^b   Bovin, Ann ^b,c   Refsgaard, Jens ^a   Abrahamsen, Jan ^a   Møller, Niels ^b   Bøtker, Hans Erik ^b   Nørrelund, Helene ^b  

^a VIBORG HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c HERNING HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; SOMATOMEDIN C; SPIRONOLACTONE; SULFONYLUREA; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD PRESSURE MONITORING; BODY COMPOSITION; CARDIOPULMONARY EXERCISE TEST; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOCARDIOGRAPHY; EVALUATION AND FOLLOW UP; EXERCISE; FATTY ACID BLOOD LEVEL; FEMALE; FLUID RETENTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUESTIONNAIRE;

EID: 85006184545     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2016-000202     Document Type: Article

References (37)

1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29–34.
2. Gitt AK, Halle M, Hanefeld M, et al. Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without? Eur J Heart Fail 2012;14:1389–400.
3. Egstrup M, Schou M, Gustafsson I, et al. Oral glucose tolerance testing in an outpatient heart failure clinic reveals a high proportion of undiagnosed diabetic patients with an adverse prognosis. Eur J Heart Fail 2011;13:319–326.
4. Sarma S, Mentz RJ, Kwasny MJ, et al. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 2013;15:194–202.
5. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503–2515.
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412.
7. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497.
8. Dargie HJ, Hildebrandt PR, Riegger GAJ, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007;49:1696–1704.
9. Barzilay JI, Kronmal RA, Gottdiener JS, et al. The association of fasting glucose levels with congestive heart failure in diabetic adults > or =65 years: the Cardiovascular Health Study. J Am Coll Cardiol 2004;43:2236–2241.
10. Held C, Gerstein HC, Yusuf S, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007;115:1371–1375.
11. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583–590.
12. Rydén L, Grant PJ, Anker SD, et al., Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Diab Vasc Dis Res 2014;11:133–173.
13. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 2006;151:91.e1–e6.
14. Opie LH. The metabolic vicious cycle in heart failure. Lancet 2004;364:1733–1734.
15. Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol 2009;54:1637–1646.
16. Nørrelund H, Wiggers H, Halbirk M, et al. Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. J Intern Med 2006;260:11–21.
17. Christensen H, Schou M, Goetze J, et al. Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction. BMC Cardiovasc Disord 2013;13:1–6.
18. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol 2002;85:51–66.
19. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050–1053.
20. Chow LS, Albright RC, Bigelow ML, et al. Mechanism of insulin’s anabolic effect on muscle: measurements of muscle protein synthesis and breakdown using aminoacyl-tRNA and other surrogate measures. Am J Physiol Endocrinol Metab 2006;291:E729–E736.
21. Heck PM, Hoole SP, Khan SN, et al. Hyperinsulinemia improves ischemic LV function in insulin resistant subjects. Cardiovasc Diabetol 2010;9:27.
22. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;281:785–789.
23. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol 2000;278:H1345–H1351.
24. Sozzi FB, Elhendy A, Roelandt JRTC, et al. Prognostic value of dobutamine stress echocardiography in patients with diabetes. Diabetes Care 2003;26:1074–1078.
25. Nielsen R, Nørrelund H, Kampmann U, et al. Effect of acute hyperglycemia on left ventricular contractile function in diabetic patients with and without heart failure: two randomized cross-over studies. PLoS ONE 2013;8:e53247.
26. Nielsen R, Nørrelund H, Kampmann U, et al. Failing heart of patients with type 2 diabetes mellitus can adapt to extreme short-term increases in circulating lipids and does not display features of acute myocardial lipotoxicity. Circ Heart Fail 2013;6:845–852.
27. Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 2006;61:1059–1064.
28. Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J 2013;34:512–519.
29. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735–743.
30. Lopez-Jaramillo P, Cohen DD, Gómez-Arbeláez D, et al. Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial. Int J Cardiol 2014;174:458–461.
31. Izawa KP, Watanabe S, Osada N, et al. Handgrip strength as a predictor of prognosis in Japanese patients with congestive heart failure. Eur J Cardiovasc Prev Rehabil 2009;16:21–27.
32. Izawa KP, Watanabe S, Hiraki K, et al. Muscle strength in heart failure Male patients complicated by diabetes mellitus. Int J Cardiol 2013;168:551–552.
33. Park SW, Goodpaster BH, Strotmeyer ES, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes 2006;55:1813–1818.
34. Arena R, Myers J, Williams MA, et al. Assessment of functional capacity in clinical and research settings: a scientific statement from the American Heart Association Committee on exercise, rehabilitation, and prevention of the council on clinical cardiology and the council on cardiovascular nursing. Circulation 2007;116:329–343.
35. Aguilar D, Chan W, Bozkurt B, et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011;4:53–58.
36. Gerstein HC, Miller ME, Byington RP, et al., ACCORD study group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008;358:2545–2559.
37. Eichhorn EJ, Grayburn PA, Mayer SA, et al. Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST). Circulation 2003;108:2336–41.